Elicio Therapeutics, Inc. · NASDAQ:ELTX
Elicio Therapeutics — Investor Presentation (January 2024)
24 slides from Elicio Therapeutics's investor presentation, Jan 9, 2024
Slide 1: Targeting the Lymph Nodes to AMPlify Immunotherapy
Targeting the Lymph Nodes to AMPlify Immunotherapy January 2024
Slide 2: Disclaimers: Forward-Looking Statements
Disclaimers Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, kno
Slide 3: Company Highlights
Company HighlightsClinical-stage biotech pioneering novel lymph node targeted cancer immunotherapies 3 Novel Approach to Immunotherapy Amphiphile or “AMP” platform traffics payloads to lymph nodes to generate robust immune responses ELI-002: A Unique Lymph Node Targeted Vaccine Designed to target 7
Slide 4: Pipeline
PipelineInnovative pipeline of cancer immunotherapies addressing critical unmet needs 4 CRC: colorectal carcinoma | PDAC: Pancreatic pancreatic ductal adenocarcinoma mKRAS: mutant Kirsten rat sarcoma | mBRAF: mutant homolog B of the Rapidly Accelerated Fibrosarcoma | mTP53: mutant tumor protein p53
Slide 5: Elicio: Amplifying Immunotherapy
Elicio: Amplifying Immunotherapy
Slide 6: The AMP Platform
The AMP PlatformHarnessing the untapped potential of the lymph nodes for immunotherapy 6 Most immune cells are located in lymph nodes, yet these critical sites are not engaged by conventional immunotherapies AMP promotes targeted delivery of payloads to the lymph nodes via “albumin hitchhiking” AMP
Slide 7: ELI-002 Composition
ELI-002 CompositionLymph node targeted therapeutic vaccine comprised of AMP-peptides and AMP-CpG 7 G12X G13X D R V C S A D ELI-002 Albumin Binding Lipid for Lymph Node Targeting CpG DNA: TLR-9 Agonist X X Albumin Binding Lipid for Lymph Node Targeting mKRAS Peptide PEG Linker • 2 or 7 AMP-peptides •
Slide 8: Mechanism of Action
Mechanism of ActionAMP immunotherapy generates an anti-tumor immune response via the lymph nodes 8 Tumor Eradication 5 Subcutaneous injection 1 Lymph Node Lymph node targeting 3 Antigen Presenting Cell Delivery to immune cells 4 Albumin-bound Amphiphiles Albumin-bound Amphiphiles Endogenous Albumin
Slide 9: The mKRAS Opportunity
The mKRAS OpportunityELI-002 targets the 7 most common KRAS mutations driving 25% of solid tumors 9 Incidence for the 7 Major Markets (MM): US, France, Germany, Italy, Spain, UK, and Japan Sources for tumor incidence obtained from GLOBOCAN (2020). PDAC: 90% of pancreatic cancers (O’Reilly, 2021), NS
Slide 10: ELI-002's Differentiated Approach to mKRAS
ELI-002’s Differentiated Approach to mKRASEarly mKRAS-targeting efforts in the clinic, while promising, leave significant white space 10 7 key mutations Reduced risk of resistance mechanisms Potent activation of immune mechanisms Expansion/activationof T cell response Promotion of anti-tumor T cell
Slide 11: ELI-002: Clinical Development Program
ELI-002: Clinical Development Program
Slide 12: ELI-002 At-a-Glance
ELI-002 At-a-GlancemKRAS immunotherapy eliciting strong T cell activity leveraging the AMP platform’s lymph node targeting design 12 2 Peptide (2P) & 7 Peptide (7P) Formulations 2P used in Phase 1 AMPLIFY-201 for clinical proof-of-concept while 7P CMC finalized Program now switches to full 7P formul
Slide 13: AMPLIFY-201 Study Overview
AMPLIFY-201 Study OverviewPhase 1 dose-ranging study to assess safety and efficacy of ELI-002 2P as adjuvant treatment in patients who completed standard therapy and have molecular disease 13 20-Months Follow-up Boost(4 doses over 4 weeks) Prime(6 doses over 8 weeks) Local Therapy(e.g., Surgery, Che
Slide 14: AMPLIFY-201: Tumor Biomarker Responses
AMPLIFY-201: Tumor Biomarker ResponsesRobust responses observed across tumor types and KRAS mutations with ELI-002 monotherapy 14 24% of patients (6/25) showed complete clearance of ctDNA Most patients (84%, 21/25) showeddecline from baseline in ctDNA or CEA/CA19-9 levels 44% (11/25) showed a >30% r
Slide 15: AMPLIFY-201: 84% patients generated mKRAS specific T Cells
AMPLIFY-201: 84% patients generated mKRAS specific T Cells 15 84% of patients showed T cell responses 100% in two highest dose cohorts, including at the RP2D (10 mg) 58x average fold-change in T cell numbers from baseline (median 13x; range 2-423x) T cells detectable by standard directex vivo Fluoro
Slide 16: AMPLIFY-201: T Cell Fold-Change Predicts Tumor Biomarker Response
Clearance Reduction Non-Responder AMPLIFY-201: T Cell Fold-Change Predicts Tumor Biomarker ResponseAll patients with T cell responses over median showed tumor biomarker response 16 Strength of T cell response to ELI-002 is strongly correlated to tumor biomarker response 100% of the above median T ce
Slide 17: T cell response correlated to tumor response and duration
17 Strength of T cell response to ELI-002 is correlated to tumor response and duration of ELI-002 administration Patients with both CD4 and CD8 T cell responses have favorable clinical outcomes mKRAS T Cell Response Clinical Response AMPLIFY-201: Majority of Above Median T Cell Responders Include CD
Slide 18: AMPLIFY-201: Above Median T Cell Responders Median RFS Significantly Prolonged
AMPLIFY-201: Above Median T Cell Responders Median RFS Significantly Prolonged86% reduction in the risk of progression or death in above median T cell responders 18 At a median follow up of 8.5 months, median RFS was not reached for above median T cell responders1 compared to 4.01 months among below
Slide 19: AMPLIFY-201: Safety & Tolerability
AMPLIFY-201: Safety & TolerabilityELI-002 was well tolerated at all dose levels, with no DLTs or SAEs 19 No Grade 3/4 TEAEs, no CRS, no DLTs at time of data cutoff (6-Sept-2023) 11/25 (44%) had Grade 1 or 2 AEs 3/25 (12%) had injection site reactions 10 mg dose selected as RP2D for Phase 1/2 AMPLIFY
Slide 20: AMPLIFY-201: T Cell Tumor Infiltration
AMPLIFY-201: T Cell Tumor InfiltrationPreliminary clinical evidence shows dense T cell tumor infiltration following ELI-002 therapy 20 72 T cells/hpf at time of progression,29x the expected 2-3 T cells / hpf in PDAC 1 T cell tumor infiltration was associated with complete ctDNA clearance in this pat
Slide 21: AMPLIFY-201: Clinical Data Summary
AMPLIFY-201: Clinical Data SummaryELI-002 monotherapy generates robust immune response that correlates with clinical benefit 21 Well Tolerated No Dose Limiting Toxicity No Grade 3/4 TEAEs, no CRS, No DLTs; 11/25 (44%) had Grade 1 or 2 AEs Promising Preliminary Data Significant reduction in risk of p
Slide 22: ELI-002 Differentiation
ELI-002 Differentiation*Distinct clinical and operational advantages over comparable cancer vaccines 22 ELI-002 SLATE-KRAS - - GRANITE - - - ** - Autogene-cevumeran - - ** - mRNA-4157 - - ** - Enhanced immune responses, no spleen requirement Broadest coverage vs driver mutations, limits resistance F
Slide 23: Continuing Execution Momentum into 2024
Continuing Execution Momentum into 2024 23 AMPLIFY-201 Updated Clinical data (1Q-2024) AMPLIFY-7P PDAC Phase 2 Initiation (1Q-2024) AMPLIFY-7P Phase 1a data (1H-2024) AMPLIFY-201 Clinical Immune (1H-2024) Response follow up 2024 Anticipated Milestones 2023 Accomplishments AMPLIFY-201 Completed Phase
Slide 24: Targeting the Lymph Nodes to AMPlify Immunotherapy
Targeting the Lymph Nodes to AMPlify Immunotherapy January 2024
Elicio Therapeutics — Investor Presentation (January 2024) on 6ix